Related Experiment Videos
Study designs for evaluating different efficacy and effectiveness aspects of vaccines
M E Halloran1, C J Struchiner, I M Longini
1Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
American Journal of Epidemiology
|December 31, 1997
Summary
This study introduces a framework for designing vaccine studies. It guides researchers in selecting appropriate comparison groups and parameters to accurately measure vaccine efficacy and effectiveness (VE) for various research questions.
Area of Science:
- Epidemiology
- Biostatistics
- Public Health
Background:
- Vaccine efficacy and effectiveness (VE) are typically quantified as 1 minus the relative risk (RR) observed in vaccinated versus unvaccinated individuals.
- Evaluating vaccination requires careful consideration of the specific research question and the appropriate comparison population and parameter.
Purpose of the Study:
- To present a framework for designing studies evaluating vaccination.
- To link specific scientific questions to appropriate study designs, comparison groups, and effect parameters.
Main Methods:
- The study proposes a framework that connects the scientific question of interest to key study design elements.
- These elements include the choice of comparison groups, the unit of observation, data availability, and the parameter of effect.
Main Results:
- The framework addresses various research interests, including the direct biologic effects of vaccines on susceptibility, infectiousness, and disease progression.
- It also considers indirect effects, total effects, and the broader public health impact of vaccination programs.
- The framework acknowledges the potential influence of behavioral changes on VE estimates.
Conclusions:
- The choice of study design, comparison group, and parameter is critical for accurately assessing vaccine effects.
- This framework provides a structured approach to ensure that study designs align with the intended research questions and objectives.